🔗 Share this article

While the United States proceeds with sweeping revisions to its vaccination recommendations, an unexpected name appears unexpectedly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who first made her name by expressing skepticism about coronavirus vaccines in the pandemic and has zeroed in on possible deaths after Covid vaccination in her recent position at the Food and Drug Administration.

Planned Overhauls to Childhood Vaccine Program

Health officials planned to unveil major revisions to the childhood immunization program earlier this month, synchronizing the US with the Danish immunization schedule, according to reports – a substantial departure that would put the US out of step with many the global community with no evidence for benefit. The announcement has been postponed until the next year.

Rather than the director of the vaccine center, Tracy Beth Høeg is listed to present at the event. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the center this year.

A New Direction at the FDA

This interim role may indicate a tighter collaboration between the drug and vaccine branches as Høeg and Dr. Prasad solidify control at the agency – and it suggests a increased emphasis upon reevaluating long-standing vaccines at the FDA.

The new acting director has repeatedly called for ending specific pediatric vaccine recommendations in the US to become more similar to Denmark's approach, a country with comprehensive healthcare and a number of inhabitants roughly the size of Wisconsin’s.

To date public appearances, she has continued to focus on vaccination policy – traditionally the responsibility of Prasad, chief of the FDA’s CBER – rather than drug regulation.

Concerns Over Qualifications

Høeg has no apparent background in medication creation, oversight or management, which has been customary for former heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the commissioner and the vaccine center since March.

“She doesn’t seem to have any of the qualifications” for running the CDER, said a neurologist and psychiatrist. “She has not conducted a scientific study. She is not versed in leading a sizeable institution. She lacks background in pharmaceutical oversight.”

Past directors of CBER would “be deeply familiar with regulatory frameworks and the research of drug development”, commented Dr. Janet Woodcock. “Frankly, she lacks the sort of resume that prior appointees who headed the center have had.”

The drug center has an vast workload at the agency, Woodcock emphasized.

“Many people just focuses on the new drug program, but the generic drug division authorizes numerous generic drugs. There’s a biologic copycat branch, OTC medication office and other areas, and all of those must be supervised,” Woodcock noted. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

There is also, a substantial leadership element to the job, which manages over 5,000 employees. “It’s a enormous administrative position, if you perform it correctly,” the former official added.

Agency Reaction and Disputed Policies

Regarding questions about Høeg’s fitness for the role and whether this assignment signifies greater collaboration among regulatory chiefs on immunizations, a representative stated that the “concerns rely on inaccurate premises”.

“This background is consistent with the duties of her position,” the official explained, citing the period Dr. Høeg spent guiding the agency head on “pharmaceutical safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Høeg takes over the agency head's recently launched priority voucher program, a contentious one-day drug-approval program that allegedly concerned her preceding directors. “How are these therapies being picked for this voucher program? Who is making the choices?” Howard questioned. “There’s a lot of lack of transparency occurring at the FDA right now.”

Overall, he stated, “the agency looks to be trending towards more relaxed regulations of most medications, except for vaccines.”

Documented Track Record on Vaccines

Concerning vaccines, Høeg has a more established, if troubling, past, critics said. She authored a analysis using unverified public submissions to assess the frequency of myocarditis after COVID-19 immunization. She advised the Florida surgeon general Dr. Joseph Ladapo, who allegedly have modified findings to imply Covid vaccines are riskier than they are.

Among her “policy goals” for the incoming government included changing regulations for recently developed shots and discontinuing “non-essential” vaccines, she said post-election on a audio program. At the FDA, Høeg has according to sources proposed preventing young men from receiving Covid vaccines.

“She’s an all-around ideologue who commences with her beliefs and works backwards to fit the evidence in a extremely misleading, fraudulent way,” Dr. Howard stated.

Gaining Influence and a “Revenge Tour”

Høeg became part of other contrarians, {like|